Copyright 2017 American Medical Association. All Rights Reserved.
In the February 2016 issue of JAMA Pediatrics, Boukhris and colleagues1 reported that in utero exposure to selective serotonin reuptake inhibitors (SSRIs) was associated with a significantly increased risk for autism. The authors examined all pregnancies from 1998 to 2009 in the Québec Pregnancy/Children Cohort database that resulted in children with autism spectrum disorder (ASD) as the primary outcome. Among 145 456 full-term infants included in the analysis, 1054 children were diagnosed with ASD by the mean age of 6.2 years (SD, 3.2 years) at follow-up, including 1008 cases of ASD among 140 732 children (0.72%) who were not exposed to antidepressants, and 31 cases of ASD among the 2532 (1.2%) children who were exposed to SSRIs during the second or third trimester. Based on these results, the authors concluded that second- or third-trimester exposure to SSRIs was associated with increased risk for ASD (adjusted hazard ratio, 1.87; 95% CI, 1.15-3.04).
King BH. Association Between Maternal Use of SSRI Medications and Autism in Their Children. JAMA. 2017;317(15):1568–1569. doi:10.1001/jama.2016.20614
Customize your JAMA Network experience by selecting one or more topics from the list below.